Scpharmaceuticals (NASDAQ:SCPH) Rating Increased to Buy at ValuEngine

Scpharmaceuticals (NASDAQ:SCPH) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.

Several other research firms have also recently issued reports on SCPH. Zacks Investment Research cut Scpharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th. HC Wainwright initiated coverage on Scpharmaceuticals in a report on Tuesday, October 15th. They set a “buy” rating and a $13.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $8.00.

Scpharmaceuticals stock opened at $4.29 on Thursday. Scpharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $7.85. The stock has a fifty day moving average of $5.59 and a two-hundred day moving average of $4.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 6.04 and a current ratio of 6.04. The company has a market capitalization of $95.88 million, a price-to-earnings ratio of -2.70 and a beta of 0.79.

Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. On average, analysts forecast that Scpharmaceuticals will post -1.77 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of SCPH. Morgan Stanley boosted its holdings in shares of Scpharmaceuticals by 32.0% during the second quarter. Morgan Stanley now owns 13,633 shares of the company’s stock worth $43,000 after purchasing an additional 3,306 shares during the last quarter. Matisse Capital acquired a new stake in shares of Scpharmaceuticals during the third quarter worth $86,000. Paloma Partners Management Co acquired a new position in Scpharmaceuticals in the second quarter valued at $96,000. Jacobs Levy Equity Management Inc. boosted its holdings in Scpharmaceuticals by 55.8% in the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock valued at $118,000 after acquiring an additional 13,225 shares during the last quarter. Finally, Alambic Investment Management L.P. acquired a new position in Scpharmaceuticals in the second quarter valued at $191,000. Institutional investors and hedge funds own 39.66% of the company’s stock.

About Scpharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Recommended Story: Why do companies engage in swaps?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.